Integra LifeSciences Holdings Corporation (IART)
Market Cap | 4.98B |
Revenue (ttm) | 1.57B |
Net Income (ttm) | 172.99M |
Shares Out | 83.52M |
EPS (ttm) | 2.06 |
PE Ratio | 28.94 |
Forward PE | 16.18 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 373,124 |
Open | 59.92 |
Previous Close | 60.49 |
Day's Range | 58.91 - 60.65 |
52-Week Range | 40.67 - 68.29 |
Beta | 1.13 |
Analysts | Buy |
Price Target | 59.57 (-0.07%) |
Earnings Date | Feb 22, 2023 |
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumenta... [Read more]
Financial Performance
In 2021, IART's revenue was $1.54 billion, an increase of 12.43% compared to the previous year's $1.37 billion. Earnings were $169.08 million, an increase of 26.28%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is $59.57, which is a decrease of -0.07% from the latest price.
News

Why Integra (IART) Could Beat Earnings Estimates Again
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
Fourth Quarter 2022

Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president a...

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates
PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed i...

Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase
Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes

Integra's (IART) Q3 Earnings Top, Gross Margin Declines
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.

Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences Reports Third Quarter 2022 Financial Results
PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third...

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022
PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial res...

Integra LifeSciences Announces Key Executive Appointment
PRINCETON, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced the appointment of Harvinder Singh as executive vice president and president...

Integra LifeSciences Publishes Its Inaugural ESG Report
The report underscores the company's long-standing commitment to improving the health of patients and the planet. The report underscores the company's long-standing commitment to improving the health ...

Here's Why Investors Should Retain Integra (IART) Stock for Now
Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Integra LifeSciences Announces Participation in Upcoming Investor Conferences
PRINCETON, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in t...

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO
PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founde...

Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences Reports Second Quarter 2022 Financial Results
PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the secon...

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences Appoints Renee Lo as Director
PRINCETON, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to...

Integra LifeSciences to Host Second Quarter 2022 Financial Results Conference Call on July 27, 2022
PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) --) Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial ...

Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integra (IART) Gains From Innovation Amid Cost Constraints
Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.

Integra (IART) Q1 Earnings Top Estimates, Margins Expand
Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.